Cluster Headache Syndrome – Pipeline Review, H2 2018

Global Markets Direct’s, ‘Cluster Headache Syndrome – Pipeline Review, H2 2018’, provides an overview of the Cluster Headache Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cluster Headache Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cluster Headache Syndrome and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Cluster Headache Syndrome

– The report reviews pipeline therapeutics for Cluster Headache Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Cluster Headache Syndrome therapeutics and enlists all their major and minor projects

– The report assesses Cluster Headache Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Cluster Headache Syndrome

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Cluster Headache Syndrome

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Cluster Headache Syndrome pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Center Laboratories Inc

Crossject SA

Eli Lilly and Co

Novartis AG

Teva Pharmaceutical Industries Ltd

TrioxBio Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cluster Headache Syndrome Overview

Cluster Headache Syndrome Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Cluster Headache Syndrome Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cluster Headache Syndrome Companies Involved in Therapeutics Development

Center Laboratories Inc

Crossject SA

Eli Lilly and Co

Novartis AG

Teva Pharmaceutical Industries Ltd

TrioxBio Inc

Cluster Headache Syndrome Drug Profiles

fremanezumab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

galcanezumab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MTR-108 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pasireotide Drug Profile

Product Description

Mechanism Of Action

R&D Progress

psilocybin Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sumatriptan Drug Profile

Product Description

Mechanism Of Action

R&D Progress

verapamil hydrochloride Drug Profile

Product Description

Mechanism Of Action

R&D Progress

zucapsaicin Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cluster Headache Syndrome Dormant Projects

Cluster Headache Syndrome Product Development Milestones

Featured News & Press Releases

Jun 15, 2018: Teva Provides Update on Clinical Trial of Fremanezumab for Use in Chronic Cluster Headache

May 15, 2018: Lilly's Galcanezumab Meets Primary Endpoint in Phase 3 Study Evaluating Galcanezumab for the Prevention of Episodic Cluster Headache

Apr 17, 2018: Teva to Present New Data on Fremanezumab at 70th Annual Meeting of the American Academy of Neurology

Sep 06, 2017: Lilly To Present New Data For Galcanezumab At The 18th Congress Of The International Headache Society

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Cluster Headache Syndrome, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Cluster Headache Syndrome Pipeline by Center Laboratories Inc, H2 2018

Cluster Headache Syndrome Pipeline by Crossject SA, H2 2018

Cluster Headache Syndrome Pipeline by Eli Lilly and Co, H2 2018

Cluster Headache Syndrome Pipeline by Novartis AG, H2 2018

Cluster Headache Syndrome Pipeline by Teva Pharmaceutical Industries Ltd, H2 2018

Cluster Headache Syndrome Pipeline by TrioxBio Inc, H2 2018

Cluster Headache Syndrome Dormant Projects, H2 2018

List of Figures

List of Figures

Number of Products under Development for Cluster Headache Syndrome, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports